Distinct p53 genomic binding patterns in normal and cancer-derived human cells

Area of Science:

• Genomics
• Molecular Biology
• Epigenetics

Background:

• The tumor suppressor p53 is a critical transcription factor involved in cell cycle regulation and DNA repair.
• Previous genome-wide studies have primarily focused on p53 binding sites in cancer cells, leaving their landscape in normal cells largely uncharacterized.

Purpose of the Study:

• To perform the first genome-wide, de novo mapping of p53 binding sites in normal human cells.
• To characterize the genomic features and epigenetic context of p53 binding sites in normal fibroblasts.
• To compare these findings with p53 binding sites in cancer-derived cells.

Main Methods:

• Chromatin immunoprecipitation sequencing (ChIP-seq) was employed to identify p53 binding sites in normal IMR90 fibroblasts.
• Bioinformatic analysis was used to determine the location and characteristics of ChIP-seq peaks.
• Comparison with existing methylome data for IMR90 cells was performed.

Main Results:

• 743 high-confidence p53 binding sites were identified in normal IMR90 cells.
• Over 40% of these sites were located within 2 kb of a transcription start site (TSS).
• Nearly half of the binding sites were found in CpG islands, contrasting with findings in cancer cells.
• p53 binding sites in normal cells were enriched at hypomethylated DNA regions.
• The de novo p53 motif was similar to those found in cancer cells, suggesting sequence is not the primary differentiator.

Conclusions:

• p53 binding sites exhibit distinct genomic landscapes in normal versus cancer-derived human cells.
• The chromatin landscape, particularly DNA methylation, likely influences p53 binding availability in normal cells.
• This study provides a foundational understanding of p53's genomic interactions in a healthy cellular context.